[Form 4] Akero Therapeutics, Inc. Insider Trading Activity
Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), filed a Form 4 reporting transactions dated 08/12/2025. The filing shows transactions effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025. The report records an acquisition of 12,500 common shares (and concomitant acquisition of 12,500 stock option rights with an exercise/conversion price of $21.10) and two sales totaling 12,500 shares sold at weighted-average prices of $47.721 and $48.324, respectively.
Following the reported activity the filing lists 197,484 shares beneficially owned directly and derivative holdings of 69,982 option-related instruments. The filing discloses three irrevocable trusts each holding 20,000 shares for the benefit of the reporting person鈥檚 children and states the reporting person disclaims beneficial ownership of those trust shares. The option referenced vests in 48 equal monthly installments commencing December 8, 2021.
Jonathan Young, Chief Operating Officer di Akero Therapeutics (AKRO), ha depositato un Modulo 4 relativo a operazioni datate 08/12/2025. Il documento indica che le operazioni sono state eseguite ai sensi di un piano di negoziazione Rule 10b5-1 datato 29 aprile 2025. La segnalazione registra l'acquisto di 12,500 azioni ordinarie (e la contestuale acquisizione di 12,500 diritti di opzione con prezzo di esercizio/conversione di $21.10) e due vendite per un totale di 12,500 azioni vendute a prezzi medi ponderati di $47.721 e $48.324, rispettivamente.
A seguito delle operazioni segnalate il deposito indica la detenzione diretta beneficiaria di 197,484 azioni e posizioni derivati relative a opzioni per 69,982 strumenti. Il filing riporta tre trust irrevocabili ciascuno con 20,000 azioni a beneficio dei figli della persona che segnala e specifica che il soggetto dichiara di non avere la propriet脿 beneficiaria di tali azioni. L'opzione menzionata matura in 48 rate mensili uguali a partire dall'8 dicembre 2021.
Jonathan Young, Chief Operating Officer de Akero Therapeutics (AKRO), present贸 un Formulario 4 que informa operaciones con fecha 08/12/2025. El documento indica que las operaciones se llevaron a cabo en virtud de un plan de negociaci贸n Rule 10b5-1 fechado el 29 de abril de 2025. El informe registra la adquisici贸n de 12,500 acciones ordinarias (y la adquisici贸n simult谩nea de 12,500 derechos de opci贸n con un precio de ejercicio/conversi贸n de $21.10) y dos ventas por un total de 12,500 acciones vendidas a precios promedio ponderados de $47.721 y $48.324, respectivamente.
Tras las operaciones notificadas, el formulario indica la tenencia beneficiaria directa de 197,484 acciones y posiciones derivadas vinculadas a opciones por 69,982 instrumentos. El informe revela tres fideicomisos irrevocables, cada uno con 20,000 acciones en beneficio de los hijos de la persona que informa, y afirma que el informante renuncia a la propiedad beneficiaria de esas acciones. La opci贸n citada devenga en 48 cuotas mensuales iguales a partir del 8 de diciembre de 2021.
Jonathan Young, Akero Therapeutics(AKRO) 斓滉碃鞖挫榿毂呾瀯鞛�(Chief Operating Officer),電� 2025雲� 08/12鞚检瀽 瓯半灅毳� 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滌棎電� 2025雲� 4鞗� 29鞚检瀽 Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 瓯半灅臧� 鞁ろ枆霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 12,500 氤错喌欤�鞚� 旆摑(霃欖嫓鞐� 頄夓偓/鞝勴櫂臧�瓴� $21.10鞚� 12,500臧滌潣 鞀ろ啞鞓奠厴 甓岆Μ 旆摑)瓿� 頃╆硠 12,500欤�鞐� 雽�頃� 霊� 瓯挫潣 毵る弰臧� 臧侁皝 臧�欷戫弶攴� 臧�瓴� $47.721 氚� $48.324搿� 鞚措（鞏挫 靷嫟鞚� 旮半霅橃柎 鞛堨姷雼堧嫟.
氤搓碃霅� 瓯半灅 鞚错泟 鞝滌稖靹滊姅 歆侅爲 鞁れ 靻岇湢頃� 197,484欤�鞕� 鞓奠厴 甏�霠� 韺岇儩靸來拡 氤挫湢 69,982瓯挫潉 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 氤搓碃鞛愳潣 鞛愲厐毳� 鞙勴暣 臧侁皝 20,000欤�毳� 氤挫湢頃� 靹� 臧滌潣 攵堦皜鞐� 鞁犿儊鞚� 瓿店皽霅橃柎 鞛堨溂氅�, 氤搓碃鞛愲姅 頃措嫻 鞁犿儊 欤检嫕鞐� 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙暅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞏戈笁霅� 鞓奠厴鞚� 2021雲� 12鞗� 8鞚茧秬韯� 毵れ洈 霃欖澕頃� 旮堨暋鞙茧 48須岇棎 瓯胳硱 氩犾姢韺呺惄雼堧嫟.
Jonathan Young, Chief Operating Officer d'Akero Therapeutics (AKRO), a d茅pos茅 un formulaire 4 d茅clarant des op茅rations dat茅es du 08/12/2025. Le d茅p么t indique que les op茅rations ont 茅t茅 effectu茅es en vertu d'un plan de n茅gociation Rule 10b5-1 dat茅 du 29 avril 2025. Le rapport enregistre l'acquisition de 12,500 actions ordinaires (et l'acquisition concomitante de 12,500 droits d'option avec un prix d'exercice/de conversion de $21.10) ainsi que deux ventes totalisant 12,500 actions vendues 脿 des prix moyens pond茅r茅s de $47.721 et $48.324, respectivement.
Apr猫s les op茅rations signal茅es, le d茅p么t mentionne la d茅tention directement b茅n茅ficiaire de 197,484 actions et des positions d茅riv茅es li茅es 脿 des options pour 69,982 instruments. Le document r茅v猫le trois trusts irr茅vocables, chacun d茅tenant 20,000 actions au profit des enfants de la personne d茅clarante, et indique que cette derni猫re d茅cline la propri茅t茅 b茅n茅ficiaire de ces actions. L'option mentionn茅e acquiert des droits par tranches mensuelles 茅gales sur 48 p茅riodes 脿 compter du 8 d茅cembre 2021.
Jonathan Young, Chief Operating Officer von Akero Therapeutics (AKRO), hat ein Formular 4 eingereicht, das Transaktionen datiert 08/12/2025 meldet. Die Einreichung weist aus, dass die Transaktionen gem盲脽 einem Rule-10b5-1-Handelsplan vom 29. April 2025 durchgef眉hrt wurden. Der Bericht verzeichnet den Erwerb von 12,500 Stammaktien (und die gleichzeitige Erlangung von 12,500 Optionsrechten mit einem Aus眉bung-/Umwandlungspreis von $21.10) sowie zwei Verk盲ufe, die zusammen 12,500 Aktien zu gewichteten Durchschnittspreisen von $47.721 bzw. $48.324 betreffen.
Nach den gemeldeten Gesch盲ften listet die Einreichung 197,484 direkt wirtschaftlich gehaltene Aktien und derivative Best盲nde in Form von 69,982 optionsbezogenen Instrumenten auf. Die Einreichung offenbart drei unwiderrufliche Trusts, die jeweils 20,000 Aktien zum Nutzen der Kinder der meldenden Person halten, und erkl盲rt, dass die meldende Person das wirtschaftliche Eigentum an diesen Trust-Aktien bestreitet. Die genannte Option vestet in 48 gleichen monatlichen Raten beginnend am 8. Dezember 2021.
- Transactions effected under a Rule 10b5-1 trading plan, reducing questions about opportunistic insider timing
- Full disclosure of trust holdings and disclaimer for three irrevocable trusts (20,000 shares each)
- Vesting schedule for options disclosed (48 monthly installments commencing December 8, 2021), aiding transparency
- Insider sales of 12,500 shares executed at weighted-average prices of $47.721 and $48.324, which may be perceived as insider liquidity
- Significant remaining direct holdings (reported 197,484 shares) and 69,982 derivative instruments represent ongoing insider exposure that could influence perceptions of insider alignment
Insights
TL;DR: Insider executed matched acquisition and sales under a 10b5-1 plan, leaving direct holdings at ~197k shares; activity appears pre-planned.
The Form 4 shows Jonathan Young used a Rule 10b5-1 plan to effect both an acquisition of 12,500 shares (and related options exercisable at $21.10) and the sale of 12,500 shares across multiple transactions at weighted-average prices near $47.7鈥�$48.3. The matching sizes and the explicit 10b5-1 disclosure reduce inference of opportunistic timing. The report also clarifies indirect holdings via three irrevocable trusts which the reporting person disclaims. For investors, this is informative about insider liquidity actions and remaining direct and derivative exposure.
TL;DR: Disclosure is complete and cites a pre-established trading plan; trusts and disclaimers are properly noted.
The filing includes customary governance disclosures: the trading plan date is provided, sales were consummated at specified weighted-average prices with a commitment to provide transaction-level breakdown if requested, and irrevocable trusts are identified with a disclaimer of beneficial ownership. Vesting terms for the option instruments are disclosed (48 monthly installments starting December 8, 2021). From a compliance perspective the Form 4 appears to meet Section 16 transparency expectations.
Jonathan Young, Chief Operating Officer di Akero Therapeutics (AKRO), ha depositato un Modulo 4 relativo a operazioni datate 08/12/2025. Il documento indica che le operazioni sono state eseguite ai sensi di un piano di negoziazione Rule 10b5-1 datato 29 aprile 2025. La segnalazione registra l'acquisto di 12,500 azioni ordinarie (e la contestuale acquisizione di 12,500 diritti di opzione con prezzo di esercizio/conversione di $21.10) e due vendite per un totale di 12,500 azioni vendute a prezzi medi ponderati di $47.721 e $48.324, rispettivamente.
A seguito delle operazioni segnalate il deposito indica la detenzione diretta beneficiaria di 197,484 azioni e posizioni derivati relative a opzioni per 69,982 strumenti. Il filing riporta tre trust irrevocabili ciascuno con 20,000 azioni a beneficio dei figli della persona che segnala e specifica che il soggetto dichiara di non avere la propriet脿 beneficiaria di tali azioni. L'opzione menzionata matura in 48 rate mensili uguali a partire dall'8 dicembre 2021.
Jonathan Young, Chief Operating Officer de Akero Therapeutics (AKRO), present贸 un Formulario 4 que informa operaciones con fecha 08/12/2025. El documento indica que las operaciones se llevaron a cabo en virtud de un plan de negociaci贸n Rule 10b5-1 fechado el 29 de abril de 2025. El informe registra la adquisici贸n de 12,500 acciones ordinarias (y la adquisici贸n simult谩nea de 12,500 derechos de opci贸n con un precio de ejercicio/conversi贸n de $21.10) y dos ventas por un total de 12,500 acciones vendidas a precios promedio ponderados de $47.721 y $48.324, respectivamente.
Tras las operaciones notificadas, el formulario indica la tenencia beneficiaria directa de 197,484 acciones y posiciones derivadas vinculadas a opciones por 69,982 instrumentos. El informe revela tres fideicomisos irrevocables, cada uno con 20,000 acciones en beneficio de los hijos de la persona que informa, y afirma que el informante renuncia a la propiedad beneficiaria de esas acciones. La opci贸n citada devenga en 48 cuotas mensuales iguales a partir del 8 de diciembre de 2021.
Jonathan Young, Akero Therapeutics(AKRO) 斓滉碃鞖挫榿毂呾瀯鞛�(Chief Operating Officer),電� 2025雲� 08/12鞚检瀽 瓯半灅毳� 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 鞝滌稖靹滌棎電� 2025雲� 4鞗� 29鞚检瀽 Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 瓯半灅臧� 鞁ろ枆霅� 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 12,500 氤错喌欤�鞚� 旆摑(霃欖嫓鞐� 頄夓偓/鞝勴櫂臧�瓴� $21.10鞚� 12,500臧滌潣 鞀ろ啞鞓奠厴 甓岆Μ 旆摑)瓿� 頃╆硠 12,500欤�鞐� 雽�頃� 霊� 瓯挫潣 毵る弰臧� 臧侁皝 臧�欷戫弶攴� 臧�瓴� $47.721 氚� $48.324搿� 鞚措（鞏挫 靷嫟鞚� 旮半霅橃柎 鞛堨姷雼堧嫟.
氤搓碃霅� 瓯半灅 鞚错泟 鞝滌稖靹滊姅 歆侅爲 鞁れ 靻岇湢頃� 197,484欤�鞕� 鞓奠厴 甏�霠� 韺岇儩靸來拡 氤挫湢 69,982瓯挫潉 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滌棎電� 氤搓碃鞛愳潣 鞛愲厐毳� 鞙勴暣 臧侁皝 20,000欤�毳� 氤挫湢頃� 靹� 臧滌潣 攵堦皜鞐� 鞁犿儊鞚� 瓿店皽霅橃柎 鞛堨溂氅�, 氤搓碃鞛愲姅 頃措嫻 鞁犿儊 欤检嫕鞐� 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙暅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 鞏戈笁霅� 鞓奠厴鞚� 2021雲� 12鞗� 8鞚茧秬韯� 毵れ洈 霃欖澕頃� 旮堨暋鞙茧 48須岇棎 瓯胳硱 氩犾姢韺呺惄雼堧嫟.
Jonathan Young, Chief Operating Officer d'Akero Therapeutics (AKRO), a d茅pos茅 un formulaire 4 d茅clarant des op茅rations dat茅es du 08/12/2025. Le d茅p么t indique que les op茅rations ont 茅t茅 effectu茅es en vertu d'un plan de n茅gociation Rule 10b5-1 dat茅 du 29 avril 2025. Le rapport enregistre l'acquisition de 12,500 actions ordinaires (et l'acquisition concomitante de 12,500 droits d'option avec un prix d'exercice/de conversion de $21.10) ainsi que deux ventes totalisant 12,500 actions vendues 脿 des prix moyens pond茅r茅s de $47.721 et $48.324, respectivement.
Apr猫s les op茅rations signal茅es, le d茅p么t mentionne la d茅tention directement b茅n茅ficiaire de 197,484 actions et des positions d茅riv茅es li茅es 脿 des options pour 69,982 instruments. Le document r茅v猫le trois trusts irr茅vocables, chacun d茅tenant 20,000 actions au profit des enfants de la personne d茅clarante, et indique que cette derni猫re d茅cline la propri茅t茅 b茅n茅ficiaire de ces actions. L'option mentionn茅e acquiert des droits par tranches mensuelles 茅gales sur 48 p茅riodes 脿 compter du 8 d茅cembre 2021.
Jonathan Young, Chief Operating Officer von Akero Therapeutics (AKRO), hat ein Formular 4 eingereicht, das Transaktionen datiert 08/12/2025 meldet. Die Einreichung weist aus, dass die Transaktionen gem盲脽 einem Rule-10b5-1-Handelsplan vom 29. April 2025 durchgef眉hrt wurden. Der Bericht verzeichnet den Erwerb von 12,500 Stammaktien (und die gleichzeitige Erlangung von 12,500 Optionsrechten mit einem Aus眉bung-/Umwandlungspreis von $21.10) sowie zwei Verk盲ufe, die zusammen 12,500 Aktien zu gewichteten Durchschnittspreisen von $47.721 bzw. $48.324 betreffen.
Nach den gemeldeten Gesch盲ften listet die Einreichung 197,484 direkt wirtschaftlich gehaltene Aktien und derivative Best盲nde in Form von 69,982 optionsbezogenen Instrumenten auf. Die Einreichung offenbart drei unwiderrufliche Trusts, die jeweils 20,000 Aktien zum Nutzen der Kinder der meldenden Person halten, und erkl盲rt, dass die meldende Person das wirtschaftliche Eigentum an diesen Trust-Aktien bestreitet. Die genannte Option vestet in 48 gleichen monatlichen Raten beginnend am 8. Dezember 2021.
FAQ
What did Jonathan Young (AKRO) report on Form 4 filed for 08/12/2025?
Were the transactions by Jonathan Young part of a trading plan?
How many AKRO shares does Jonathan Young beneficially own after these transactions?
Does Jonathan Young have indirect holdings disclosed on the Form 4?
What are the terms of the option vesting disclosed in the Form 4?
